Development of a Chemoproteomics Centre of Excellence: A Prosperity Partnership for Drug Discovery in Northern Ireland

BBSRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

November 21, 2028
Response Due
Active
Status

Opportunity Overview

In this BBSRC Prosperity Partnership, Queen's University Belfast (QUB) and Almac Discovery will bring together their joint expertise to create a new state-of-the-art Chemoproteomics Centre of Excellence situated within QUB; this will be the first of its kind in the Northern Ireland region. Specifically, we will use the Prosperity Partnership to co-develop a new mass spectrometry proteomics facility that can study molecular changes in proteins from cells and tissues treated with therapeutic drugs and drug-like molecules ("chemical probes"). This facility builds on a well-established relationship between the partners in basic biological research and early-stage drug discovery (Almac), leveraging the capabilities and state-of-the-art expertise of QUB researchers in mass spectrometry and basic and translational biological research (namely inflammation, cell death and ion channels) across three University Research Centres (Cancer, Experimental Medicine and Pharmacy).

The Centre of Excellence will provide completely new chemical tools that will open new areas of biology and a mass spectrometry platform that will benefit both partners, thereby enabling cutting-edge biological research and drug discovery. It is also envisaged that this facility will provide opportunities for other collaborators, both academic and industrial, to advance their basic research and R&D portfolios, providing a business model that will ensure that this Centre of Excellence will continue to support academic and industrial R&D in the region beyond the life of this project. Not only will the Centre of Excellence enhance our regional capabilities, it will also provide skills training for apprenticeships through to doctoral researchers and create value in the forms of new drugs, intellectual property and high quality academic publications (reputation). Thus, the Centre of Excellence will encourage inward investment and sectorial growth in Northern Ireland, helping to "level...

This is one of 44 active United Kingdom Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyBBSRC
CountryUnited Kingdom
CategoryPharmaceuticals
PublishedNovember 22, 2024
Procurement stageActive solicitation
Response dueNovember 21, 2028
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Pharmaceutical Wholesale Services
Community Drug and Alcohol Services
Provision of Drug, Alcohol & DNA Testing Services Framework
Personalised Adaptive Medicine
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development Company
Smallpox Vaccine (2026)
Integrated Drug and Alcohol Treatment and Recovery Service
Meningococcal ACWY vaccine (2027)

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Pharmaceuticals intelligence report in your inbox

A personalized report on United Kingdom Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.